Momentum Biotechnologies (“Momentum”), a contract research organization (“CRO”) specializing in mass spectrometry-based drug discovery, announces that it has successfully completed the acquisition of OmicScouts GmbH (“OmicScouts”), a Munich-based CRO and established leader in the field of mass spectrometry-based proteomics, operating hereafter as OmicScouts, a Momentum Biotechnologies Company. With this transaction, Momentum gains access to a broad portfolio of well-validated proteomic assays that enhance and extend their existing service offerings, enabling clients to seamlessly progress from high-throughput screening into cell-based assays, as well as to discover new targets and biomarkers.
Read the full article: Momentum Biotechnologies Announces Acquisition of OmicScouts //
Source: https://www.prnewswire.com/news-releases/momentum-biotechnologies-announces-acquisition-of-omicscouts-302392012.html